Physician profile
Carl Stein
NPI 1053346957
$14,968.93
in general payments reported to CMS, 2019-2025
12 companies · $990 in 2025
The $990 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,583 · 2022: $4,202 · 2023: $5,846 · 2024: $1,348 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,500 · Food and Beverage: $2,927 · Travel and Lodging: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,500.00 |
| Food and Beverage | $2,926.55 |
| Travel and Lodging | $757.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $12,643.80 | 2021-2025 | Cabenuva, Dovato, Apretude |
| Gilead Sciences, INC. | $766.81 | 2021-2022 | |
| Abbvie INC. | $257.20 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $221.82 | 2024-2025 | |
| Janssen Products, Lp | $179.94 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $172.13 | 2023-2025 | |
| Organon LLC | $167.86 | 2025 | Vtama |
| Madrigal Pharmaceuticals | $129.87 | 2025 | Rezdiffra |
| Intuitive Surgical, INC. | $129.74 | 2025 | |
| Lilly USA, LLC | $122.86 | 2025 | Zepbound |
| Amylyx Pharmaceuticals, INC. | $114.27 | 2023 | Relyvrio |
| Neurocrine Biosciences, INC. | $62.63 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.